267 related articles for article (PubMed ID: 19339803)
1. Intralymphatic injections as a new administration route for allergen-specific immunotherapy.
Martínez-Gómez JM; Johansen P; Erdmann I; Senti G; Crameri R; Kündig TM
Int Arch Allergy Immunol; 2009; 150(1):59-65. PubMed ID: 19339803
[TBL] [Abstract][Full Text] [Related]
2. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles.
Martínez Gómez JM; Fischer S; Csaba N; Kündig TM; Merkle HP; Gander B; Johansen P
Pharm Res; 2007 Oct; 24(10):1927-35. PubMed ID: 17541735
[TBL] [Abstract][Full Text] [Related]
3. IVN201--therapy with a construct containing functional fusion peptides.
Rose H
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():319-27; discussion 327-8. PubMed ID: 20799476
[TBL] [Abstract][Full Text] [Related]
4. Intralymphatic immunotherapy: from the rationale to human applications.
Senti G; Johansen P; Kündig TM
Curr Top Microbiol Immunol; 2011; 352():71-84. PubMed ID: 21725898
[TBL] [Abstract][Full Text] [Related]
5. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine.
Zaleska A; Eiwegger T; Soyer O; van de Veen W; Rhyner C; Soyka MB; Bekpen C; Demiröz D; Treis A; Söllner S; Palomares O; Kwok WW; Rose H; Senti G; Kündig TM; Ozoren N; Jutel M; Akdis CA; Crameri R; Akdis M
Allergy; 2014 Sep; 69(9):1162-70. PubMed ID: 24934402
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a therapeutic treatment using gas-filled microbubble-associated phospholipase A2 in a mouse model of honeybee venom allergy.
Corthésy B; Lassus A; Terrettaz J; Tranquart F; Bioley G
Allergy; 2016 Jul; 71(7):957-66. PubMed ID: 26850222
[TBL] [Abstract][Full Text] [Related]
7. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections.
Senti G; Crameri R; Kuster D; Johansen P; Martinez-Gomez JM; Graf N; Steiner M; Hothorn LA; Grönlund H; Tivig C; Zaleska A; Soyer O; van Hage M; Akdis CA; Akdis M; Rose H; Kündig TM
J Allergy Clin Immunol; 2012 May; 129(5):1290-6. PubMed ID: 22464647
[TBL] [Abstract][Full Text] [Related]
8. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Hylander T; Latif L; Petersson-Westin U; Cardell LO
J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
[TBL] [Abstract][Full Text] [Related]
9. Medication with antihistamines impairs allergen-specific immunotherapy in mice.
Johansen P; Senti G; Maria Martínez Gómez J; Kündig TM
Clin Exp Allergy; 2008 Mar; 38(3):512-9. PubMed ID: 18081882
[TBL] [Abstract][Full Text] [Related]
10. Intralymphatic immunotherapy.
Senti G; Johansen P; Kündig TM
Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):537-43. PubMed ID: 19680119
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy concepts under investigation.
Kündig TM
Allergy; 2011 Jul; 66 Suppl 95():60-2. PubMed ID: 21668859
[TBL] [Abstract][Full Text] [Related]
12. High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers.
Boonpiyathad T; Meyer N; Moniuszko M; Sokolowska M; Eljaszewicz A; Wirz OF; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A; Ruxrungtham K; van de Veen W
Allergy; 2017 Mar; 72(3):407-415. PubMed ID: 27341567
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy.
Johansen P; Senti G; Martinez Gomez JM; Storni T; von Beust BR; Wüthrich B; Bot A; Kündig TM
Clin Exp Allergy; 2005 Dec; 35(12):1591-8. PubMed ID: 16393325
[TBL] [Abstract][Full Text] [Related]
14. Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores.
Hessenberger M; Weiss R; Weinberger EE; Boehler C; Thalhamer J; Scheiblhofer S
Vaccine; 2013 Jul; 31(34):3427-34. PubMed ID: 23273971
[TBL] [Abstract][Full Text] [Related]
15. Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy.
Grundström J; Neimert-Andersson T; Kemi C; Nilsson OB; Saarne T; Andersson M; van Hage M; Gafvelin G
Int Arch Allergy Immunol; 2012; 157(2):136-46. PubMed ID: 21985799
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic immunization of mice with phospholipase A2-loaded gas-filled microbubbles is protective against Th2-mediated honeybee venom allergy.
Bioley G; Lassus A; Terrettaz J; Tranquart F; Corthésy B
Clin Exp Allergy; 2016 Jan; 46(1):153-62. PubMed ID: 25900397
[TBL] [Abstract][Full Text] [Related]
17. Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis.
von Garnier C; Astori M; Kettner A; Dufour N; Heusser C; Corradin G; Spertini F
Eur J Immunol; 2000 Jun; 30(6):1638-45. PubMed ID: 10898500
[TBL] [Abstract][Full Text] [Related]
18. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy.
Martínez-Gómez JM; Johansen P; Rose H; Steiner M; Senti G; Rhyner C; Crameri R; Kündig TM
Allergy; 2009 Jan; 64(1):172-8. PubMed ID: 19076537
[TBL] [Abstract][Full Text] [Related]
19. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.
Rask C; Lund L; Lund G; Heydenreich B; Wurtzen P; Bellinghausen I; Saloga J; Lund K
Clin Exp Allergy; 2012 Sep; 42(9):1356-68. PubMed ID: 22925322
[TBL] [Abstract][Full Text] [Related]
20. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.
Müller U; Akdis CA; Fricker M; Akdis M; Blesken T; Bettens F; Blaser K
J Allergy Clin Immunol; 1998 Jun; 101(6 Pt 1):747-54. PubMed ID: 9648701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
